Letter to the EditorThe association between vitamin D status and the rate of exacerbations requiring oral corticosteroids in preschool children with recurrent wheezing
References (13)
- et al.
Diagnosis and management of early asthma in preschool-aged children
J Allergy Clin Immunol
(2012) - et al.
The Prevention of Early Asthma in Kids study: design, rationale and methods for the Childhood Asthma Research and Education network
Control Clin Trials
(2004) - et al.
Vitamin D status in Montreal preschoolers is satisfactory despite low vitamin D intake
J Nutr
(2013) Vitamin D and atopy and asthma phenotypes in children
Curr Opin Allergy Clin Immunol
(2012)Vitamin D deficiency as a risk factor for childhood allergic disease and asthma
Curr Opin Allergy Clin Immunol
(2012)- et al.
Daily or intermittent budesonide in preschool children with recurrent wheezing
N Engl J Med
(2011)
Cited by (29)
Polyphenols and their potential role to fight viral diseases: An overview
2021, Science of the Total EnvironmentVitamin D can safely reduce asthma exacerbations among corticosteroid-using children and adults with asthma: a systematic review and meta-analysis of randomized controlled trials
2021, Nutrition ResearchCitation Excerpt :This result was in accordance with previous studies where serum vitamin D levels were negatively correlated with the rate of asthma exacerbation among preschoolers treated with inhaled corticosteroids. Lower serum vitamin D concentration resulted in a higher rate of asthma exacerbation, which increased the required medical care and number of emergency department visits [6,27]. Our finding verified the hypothesis that vitamin D supplementation can improve the clinical efficacy of corticosteroids in patients with asthma as measured by exacerbations.
Vitamin D, high-sensitivity C-reactive protein, and airway hyperresponsiveness in infants with recurrent respiratory symptoms
2017, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :Although the role of vitamin D in asthma is not fully established, vitamin D insufficiency has been linked with worse asthma control, more exacerbations, and emergency department visits in adults1 and children with asthma.1,6,18 In recurrent preschool wheezers, vitamin D insufficiency has been associated with frequent exacerbations requiring oral corticosteroids,6 and oral supplementation of vitamin D might lessen exacerbations during treatment of lower airway symptoms with inhaled corticosteroids.19 In adults and children with asthma, vitamin D levels and vitamin D insufficiency have been associated with decreased lung function.1,2,20
Vitamin D Insufficiency and Asthma in a US Nationwide Study
2017, Journal of Allergy and Clinical Immunology: In PracticeManagement of Preschool Children with Recurrent Wheezing: Lessons from the NHLBI's Asthma Research Networks
2016, Journal of Allergy and Clinical Immunology: In Practice
This study was supported by the National Heart, Lung, and Blood Institute (grants 5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, and 5U10HL064313). This study is supported in part by the Washington University Institute of Clinical and Translational Sciences (grant no. UL1 TR000448), the National Center for Advancing Translational Sciences (subaward no. KL2 TR000450), the University of Wisconsin School of Medicine and Public Health Clinical and Translational Science Award (CTSA) (grant no. UL1 TR000427), and Colorado CTSA (grant no. 1 UL1RR025780 from the National Center for Research Resources/National Institutes of Health). This study was carried out in part in the General Clinical Research Centers at Washington University School of Medicine (M01 RR00036), at National Jewish Health (M01 RR00051), and at the University of New Mexico (M01 RR00997).
Disclosure of potential conflict of interest: A. Beigelman has received grants from the National Heart, Lung, and Blood Institute (NHLBI), the KL2 Award, and Washington University's ICTS award and is employed by the Washington University School of Medicine. R. S. Zeiger has received grants from the NHLBI, Genentech, GlaxoSmithKline, Aerocrine, Merck, MedImmune, and Thermofisher and has consultant arrangements with Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, MedImmune, Schering Plough, Sunovion, and the NHLBI/Penn State. D. Mauger has received a grant from the NHLBI; has received payment for providing writing assistance, medicines, equipment, or administrative support from AstraZeneca; and has consultant arrangements with GlaxoSmithKline, Boerhinger Ingelheim, and Merck. R. C. Strunk has received a grant from the NHLBI. D. J. Jackson has received grants from the National Institutes of Health (NIH) and Pharmaxis and has consultant arrangements with Gilead and GlaxoSmithKline. F. D. Martinez has received a grant from the NIH; has consultant arrangements with MedImmune; has received payment for lectures from Abbott and Merck; and has received travel support from Abbott and Merck. W. J. Morgan has received grants from the NHLBI, the Cystic Fibrosis Foundation, and the National Institute of Allergy and Infectious Disease; has consultant arrangements with the Cystic Fibrosis Foundation and Genentech; is employed by the University of Arizona; has received payment for lectures from Northwestern University, Indiana University, and St Jude's; and has received royalties from Elsevier. R. Covar has received grants from the NHLBI, GlaxoSmithKline, and Boehringer Ingelheim and has consultant arrangements with United Biosource. S. J. Szefler has received a grant, travel support, fees for participation in review activities, and payment for writing/reviewing the manuscript from the NHLBI; has consultant arrangements with Merck, Genentech, Boehringer Ingelheim, and GlaxoSmithKline; has received a grant from GlaxoSmithKline; has received payment for lectures from Merck; has received payment for manuscript preparation from Genentech; and has patents planned through the NHLBI Childhood Asthma Research and Education Network. L. B. Bacharier has received grants from the NHLBI; has consultant arrangements with Aerocrine, GlaxoSmithKline, Genentech/Novartis, Merck, Schering, Cephalon, and DBV; has received payment for lectures from Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, Merck, and Schering; and has received payment for manuscript preparation from First Consult. L. Taussig declares no relevant conflicts of interest.